TP53 and osteosarcoma: To compare the anticancer activity of AgNPs with a clinically applied chemotherapeutic agent on p53-expressing and p53-deficient osteosarcoma cells, U2Os and Saos-2 cells were treated with cisplatin in various concentrations and cell viabilities were determined after 24 h.